Literature DB >> 24100492

Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes.

Teena Chopra1, Dror Marchaim, Reda A Awali, Amar Krishna, Paul Johnson, Ryan Tansek, Khawar Chaudary, Paul Lephart, Jessica Slim, Jatinder Hothi, Harris Ahmed, Jason M Pogue, Jing J Zhao, Keith S Kaye.   

Abstract

Acinetobacter baumannii has become a leading cause of bloodstream infections (BSI) in health care settings. Although the incidence of infection with carbapenem- and ampicillin-sulbactam-resistant (CASR) A. baumannii has increased, there is a scarcity of studies which investigate BSI caused by CASR A. baumannii. A retrospective cohort study was conducted on adult patients with BSI caused by A. baumannii and who were admitted to the Detroit Medical Center between January 2006 and April 2009. Medical records were queried for patients' demographics, antimicrobial exposures, comorbidities, hospital stay, and clinical outcomes. Bivariate analyses and logistic regression were employed in the study. Two hundred seventy-four patients with BSI caused by A. baumannii were included in the study: 68 (25%) caused by CASR A. baumannii and 206 (75%) caused by non-CASR A. baumannii. In multivariate analysis, factors associated with BSI caused by CASR A. baumannii included admission with a rapidly fatal condition (odds ratio [OR] = 2.83, 95% confidence interval [CI] = 1.27 to 6.32, P value = 0.01) and prior use of antimicrobials (OR = 2.83, 95% CI = 1.18 to 6.78, P value = 0.02). In-hospital mortality rates for BSI caused by CASR A. baumannii were significantly higher than those for non-CASR A. baumannii-induced BSI (43% versus 20%; OR = 3.0, 95% CI = 1.60 to 5.23, P value < 0.001). However, after adjusting for potential confounders, the association between BSI caused by CASR A. baumannii and increased risk of in-hospital mortality was not significant (OR = 1.15, 95% CI = 0.51 to 2.63, P value = 0.74). This study demonstrated that CASR A. baumannii had a distinct epidemiology compared to more susceptible A. baumannii strains; however, clinical outcomes were similar for the two groups. Admission with a rapidly fatal condition was an independent predictor for both CASR A. baumannii and in-hospital mortality.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24100492      PMCID: PMC3837851          DOI: 10.1128/AAC.01520-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Molecular epidemiological investigation of multidrug-resistant Acinetobacter baumannii strains in four Mediterranean countries with a multilocus sequence typing scheme.

Authors:  A Di Popolo; M Giannouli; M Triassi; S Brisse; R Zarrilli
Journal:  Clin Microbiol Infect       Date:  2011-02       Impact factor: 8.067

Review 2.  Antibacterial resistance worldwide: causes, challenges and responses.

Authors:  Stuart B Levy; Bonnie Marshall
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

Review 3.  Tigecycline.

Authors:  George A Pankey
Journal:  J Antimicrob Chemother       Date:  2005-07-22       Impact factor: 5.790

4.  High tigecycline resistance in multidrug-resistant Acinetobacter baumannii.

Authors:  Shiri Navon-Venezia; Azita Leavitt; Yehuda Carmeli
Journal:  J Antimicrob Chemother       Date:  2007-03-12       Impact factor: 5.790

5.  Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome.

Authors:  L-C Kuo; C-C Lai; C-H Liao; C-K Hsu; Y-L Chang; C-Y Chang; P-R Hsueh
Journal:  Clin Microbiol Infect       Date:  2007-02       Impact factor: 8.067

Review 6.  Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment.

Authors:  J M Cisneros; J Rodríguez-Baño
Journal:  Clin Microbiol Infect       Date:  2002-11       Impact factor: 8.067

7.  Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia.

Authors:  Nan-Yao Lee; Hsin-Chun Lee; Nai-Ying Ko; Chia-Ming Chang; Hsin-I Shih; Chi-Jung Wu; Wen-Chien Ko
Journal:  Infect Control Hosp Epidemiol       Date:  2007-05-14       Impact factor: 3.254

8.  Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2004-11-19       Impact factor: 17.586

9.  Acinetobacter baumannii: emergence and spread in Israeli hospitals 1997-2002.

Authors:  M Paul; M Weinberger; Y Siegman-Igra; T Lazarovitch; I Ostfeld; I Boldur; Z Samra; H Shula; Y Carmeli; B Rubinovitch; S Pitlik
Journal:  J Hosp Infect       Date:  2005-07       Impact factor: 3.926

10.  Multidrug-resistant Acinetobacter baumannii.

Authors:  Aharon Abbo; Shiri Navon-Venezia; Orly Hammer-Muntz; Tami Krichali; Yardena Siegman-Igra; Yehuda Carmeli
Journal:  Emerg Infect Dis       Date:  2005-01       Impact factor: 6.883

View more
  20 in total

Review 1.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

Authors:  Darren Wong; Travis B Nielsen; Robert A Bonomo; Paul Pantapalangkoor; Brian Luna; Brad Spellberg
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

2.  Task force on management and prevention of Acinetobacter baumannii infections in the ICU.

Authors:  José Garnacho-Montero; George Dimopoulos; Garyphallia Poulakou; Murat Akova; José Miguel Cisneros; Jan De Waele; Nicola Petrosillo; Harald Seifert; Jean François Timsit; Jordi Vila; Jean-Ralph Zahar; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2015-10-05       Impact factor: 17.440

3.  Detection of AmpC β-lactamases in Acinetobacter baumannii in the Xuzhou region and analysis of drug resistance.

Authors:  Yongrui Liu; Xiangqun Liu
Journal:  Exp Ther Med       Date:  2015-07-02       Impact factor: 2.447

Review 4.  Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside.

Authors:  Ming-Feng Lin; Chung-Yu Lan
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

Review 5.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

6.  Risk factors and outcomes for patients with bloodstream infection due to Acinetobacter baumannii-calcoaceticus complex.

Authors:  Teena Chopra; Dror Marchaim; Paul C Johnson; Reda A Awali; Hardik Doshi; Indu Chalana; Naomi Davis; Jing J Zhao; Jason M Pogue; Sapna Parmar; Keith S Kaye
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

7.  Risk Factors, Clinical Presentation, and Outcome of Acinetobacter baumannii Bacteremia.

Authors:  Tala Ballouz; Jad Aridi; Claude Afif; Jihad Irani; Chantal Lakis; Rakan Nasreddine; Eid Azar
Journal:  Front Cell Infect Microbiol       Date:  2017-05-04       Impact factor: 5.293

8.  Postoperative infection caused by Acinetobacter baumannii misdiagnosed as a free-living amoeba species in a humeral head hemiarthroplasty patient: a case report.

Authors:  Jiaxin Tang; Huaimin Zhu; Li Cai; Tingting Tang; Jian Tang; Yuehua Sun; Ming Liu; Kerong Dai; Zhiguang Qiao; Chao Yu
Journal:  Infect Dis Poverty       Date:  2018-03-31       Impact factor: 4.520

9.  Distribution of virulence-associated genes and antimicrobial susceptibility in clinical Acinetobacter baumannii isolates.

Authors:  Chao Liu; Yaowen Chang; Ying Xu; Yun Luo; Linrong Wu; Zhanjun Mei; Shigang Li; Rui Wang; Xu Jia
Journal:  Oncotarget       Date:  2018-04-24

10.  Analysis of Acinetobacter baumannii hospital infections in patients treated at the intensive care unit of the University Hospital, Wroclaw, Poland: a 6-year, single-center, retrospective study.

Authors:  Wieslawa Duszynska; Agnieszka Litwin; Stanislaw Rojek; Aleksander Szczesny; Alfonso Ciasullo; Waldemar Gozdzik
Journal:  Infect Drug Resist       Date:  2018-05-01       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.